Imunoglukan Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 50
Employees
  • Latest Deal Type
  • Buyout/​LBO
  • Financing Rounds
  • 1

Imunoglukan General Information

Description

Manufacturer of immunity focused dietary supplements. The company engages in research, development and sale of immunity medicines and dietary supplements, it manufactures imunoglukan which is a highly purified natural substance, , the compex of biologically active polysaccharides obtained through the isolation from Pleurotus ostreatus.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • Nové Záhrady I č. 13/A
  • Bratislava, 821 05
  • Slovakia
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Imunoglukan Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Imunoglukan‘s full profile, request access.

Request a free trial

Imunoglukan Executive Team (2)

Name Title Board Seat Contact Info
Martin Polak Chief Executive Officer
Ján Gabriž Founder
To view Imunoglukan’s complete executive team members history, request access »

Imunoglukan Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imunoglukan Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Imunoglukan‘s full profile, request access.

Request a free trial